Company intelligence / Profile preview
TRIO Pharmaceuticals
San Diego, California, United Statestriopharmaceuticals.com ↗
- Ownership
- Private
- Development stage
- Preclinical
01
Overview
TRIO Pharmaceuticals is developing dual-targeting antibody drugs with demonstrated bioactivity for both their TRAILBody and TIE-ADC bispecific antibody architectures. The company has completed pre-Series A financing to advance their cancer therapeutics pipeline.
- Therapeutic areas
- OncologyHematology
- Modalities
- Bispecific antibodiesAntibody-drug conjugates (ADCs)
- Industry
- Biotech
02
Drug pipeline
7 assets6 more assets in the full pipeline.
Beyond the preview
Go deeper on TRIO Pharmaceuticals.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TRIO Pharmaceuticals.